ADHD

The experts weighed in on a wide variety of psychiatric issues for the August 2023 issue of Psychiatric Times.

Generics are now approved for adults in the treatment of BED and for individuals aged 6 years and older in the treatment of ADHD.

According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023. As these shortages continue, here's how you can best support your patients with ADHD.

In this CME article, learn more about the full continuum of presentations and variable trajectories typical of females with ADHD.

From an examination of the fentanyl epidemic to the connection between ADHD medication and height, here are highlights from the week in Psychiatric Times.

Doctor, how will this medication affect my child’s growth? Researchers performed a register-based study of ADHD, ADHD medication, and height.

From obesity and metabolism in first-episode MDD to psychiatrist liability and suicide, here are highlights from the week in Psychiatric Times.

New positive data was recently released from 5 in vitro studies investigating the potential for drug-drug interaction of mazindol.

Data showed good news for safety and tolerability with mixed good news for efficacy.

From adherence in addiction recovery treatment to the relationship between social media use and youth mental health, here are highlights from the week in Psychiatric Times.

Where might proponents of neurodiversity and psychiatrists agree?

What is the connection?

From collaborative care for individuals with schizophrenia and COVID-19 to strategies for building patient rapport, here are highlights from the week in Psychiatric Times.

Do ADHD symptoms impact smoking cessation outcomes? Researchers performed a randomized controlled trial of varenicline for tobacco cessation in adolescents and young adults.

Study results show that the therapy activates serotonin (5-HT) and improves stress-coping ability.

From the normalization of burnout to the identification of sleep-wake disturbances post-TBI, here are highlights from the week in Psychiatric Times.

Results show that the novel formulation of dexmethylphenidate can be taken either with or without food.

How do you “see” your patients with ADHD? Researchers performed a systematic review and meta-analysis of ADHD and vision problems.

From the effects of caffeine on smokers with schizophrenia and bipolar disorder to the initiation of a trial for a new ADHD medication, here are highlights from the week in Psychiatric Times.

The first phase 3 clinical trial of CTx-1301 for the treatment of ADHD has begun.

From new advances in the treatment of postpartum depression to digital therapeutics for the treatment of ADHD in children, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the December 2022 issue of Psychiatric Times.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

The investigators suggested that future research explore the connection between ADHD risk in children and depression in pregnant parents.

Take a look at this bread-and-butter case of ADHD from a child psychiatry clinic.

Screening for the symptom of worthlessness could save your adolescent patient’s life…

The experts weighed in on a wide variety of psychiatric issues for the November 2022 issue of Psychiatric Times.

Theresa Cerulli, MD, discusses the practical considerations for using serdexmethylphenidate-dexmethylphenidate for the treatment of attention-deficit/hyperactivity disorder.

What are the advances in adult ADHD?

Theresa Cerulli, MD, describes the indication and mechanism of the recent FDA approved combination product serdexmethylphenidate /dexmethylphenidate for the treatment of attention deficit/hyperactivity disorder (ADHD).